NPM1 and acute myeloid leukemia: To further validate these findings, we tested AraC in two NPM1-mutated AML primary samples, confirming that the non-A-like NPM1-mutated AML cells were more sensitive to the effect displayed by AraC than A-like-mutated cells (Figure 4D, ** p < 0.01).